Cargando…
Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series
Dupilumab is the first biologic registered for the treatment of atopic dermatitis (AD). We report on seven patients with AD presenting with a paradoxical head and neck erythema that appeared 10–39 weeks after the start of dupilumab treatment. The patients presented with a relatively sharply demarcat...
Autores principales: | de Wijs, L.E.M., Nguyen, N.T., Kunkeler, A.C.M., Nijsten, T., Damman, J., Hijnen, D.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586932/ https://www.ncbi.nlm.nih.gov/pubmed/31749159 http://dx.doi.org/10.1111/bjd.18730 |
Ejemplares similares
-
Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient‐reported outcome measures
por: de Wijs, L.E.M., et al.
Publicado: (2021) -
Effects of dupilumab treatment on patch test reactions: A retrospective evaluation
por: de Wijs, Linde E. M., et al.
Publicado: (2021) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023) -
Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study
por: de Wijs, Linde E. M., et al.
Publicado: (2022)